Comparison of bicyclol therapy for patients with genotype B and C of hepatitis B virus.
- Author:
Bing RUAN
1
,
2
;
Jun-wei WANG
;
Xue-ling BAI
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Biphenyl Compounds; therapeutic use; Female; Genotype; Hepatitis B virus; classification; Hepatitis B, Chronic; drug therapy; virology; Humans; Male; Middle Aged
- From: Chinese Journal of Experimental and Clinical Virology 2007;21(4):366-368
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo compare the efficacy of bicyclol tablets on patients infected with hepatitis B virus between genotype B and C.
METHODS70 patients with chronic viral hepatitis B were selected. The patients divide into two groups: HBV genotypes B (26 cases) and HBV genotypes C (other 44 cases). All patients received bicyclol tablets orally 150 mg daily (50mg, tid, po) for 24 weeks. The efficacy were observed after 12 weeks and 24 weeks.
RESULTSAfter treatment for 24 weeks, the serum aminotransferase were decreased obviously, and HBV DNA levels turn to be negative with 19.2 percent (genotype B group) and 15.9 percent (genotype C group), respectively. The difference was not statistically significant between HBV genotype B and C.
CONCLUSIONBicyclol not only has hepatoprotective activity but also inhibited virus replication in patients infected with HBV. The difference of the response to bicyclol therapy between HBV genotypes B and C was not statistically significant.
